Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2 - - GEO DataSets - NCBI

Warning: The NCBI web site requires JavaScript to function. more...

Result Filters

Summary

Format

Summary
Summary (text)
Unique Identifier List

Send to:

Choose Destination

File
Clipboard
Collections

Links from GEO Profiles

Full record GDS4095

Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2

Analysis of endocrine-resistant LY2 breast cancer cells depleted of p160 steroid coactivator protein SRC-1 and treated with tamoxifen. SRC-1 is central to the development of the endocrine resistant phenotype. Results provide insight into the molecular basis of endocrine resistant breast cancer.

Organism:: Homo sapiens

Type:: Expression profiling by array, transformed count, 2 agent, 2 genotype/variation sets

Platform:: GPL570
Series:: GSE28645
14 Samples

Download data: CEL

DataSet

Accession:: GDS4095

ID:: 4095

PubMed Full text in PMC Similar studies GEO Profiles Analyze DataSet

Supplemental Content

Related information

PubMed
Related PubMed entries
Full text in PMC
PMC links
Similar studies
Similar studies
GEO Profiles
Related GEO
BioProject
BioProject links
GEO DataSets
Related GEO DataSets
Taxonomy
Taxonomy

Important Links

Recent activity

Clear Turn Off Turn On

Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line ...
Tamoxifen effect on SRC-1-deficient endocrine-resistant breast cancer cell line LY2
Accession: GDS4095

GEO DataSets
Related DataSets for GEO Profiles (Select 78634073) (1)
GEO DataSets

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

You are here: NCBI > Genes & Expression > Gene Expression Omnibus (GEO) Datasets